Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Search
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Avenciguat (BI 685509)
Avenciguat (BI 685509)
NPY2r agonist
Food intake regulator
Vetera
For vaccination of healthy horses as an aid in the prevention of diseases caused by the included antigens (US and Canada only).
Hypertension
Hypertension
About Chronic Kidney Disease
CKD is very common and often goes undetected due to its silent nature. Risk factors include high blood pressure and type 2 diabetes.
A Unique Bond: friends in need
After suffering from a stroke, Phil’s connection with Valle helped change his life
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
NexGard Spectra
Prevents heartworm disease and treats and controls hookworm, roundworm, whipworm, and lungworm infestations in dogs and puppies.
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Action makes the difference in poultry farms
Farmers, be on the lookout to protect chickens against the ILT virus!
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Livestock
Livestock
Prascend
Symptomatic treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID; also known as equine Cushing’s disease).
Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
The Research Process
The Research Process
Retinal Health: Meet the Scientists
We aim to prevent, treat, and restore vision loss. Delve behind the lab to see our scientists spearheading research to address retinopathies.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Catherine Alonzo
Catherine Alonzo, Patient Safety Physician, Metabolism, tells us about the importance of drug surveillance.